Sexually Transmitted Diseases

Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.

Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.

It is important to go out into the local communities to educate people about PrEP as countries try to scale up with the World Health Organization’s (WHO) PrEP recommendations.

Human papillomavirus (HPV) impacts millions of Americans, and new study sought to address the epidemiology of HPV and high-grade squamous intraepithelial lesions (HSIL).

Global use of HIV pre-exposure prophylaxis has risen as more countries have adopted World Health Organization recommendations.

New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.

The adoption of numerous HIV prevention measures was associated with an 80% drop in the number of HIV diagnoses, a study evaluating the success of 56 Dean Street in London found.

What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.

A review of selected investigational long-active treatment options for HIV.

Macro and micro strategies are at play in aiming to create greater PrEP access and adoption.

A new study sought to approach the HIV epidemic in the United States through a distributional cost-effectiveness analysis across 6 cities.

An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.

Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.

Three HIV screening strategies identified comparable numbers of new HIV diagnoses, a new study found.

Patients given a 600 mg injection of cabotegravir still had detectable levels of the drug in plasma, tissues, and fluids for 12 weeks.

A recent study of sexually active young women in Africa found that initiation of HIV preexposure prophylaxis (PrEP) was high at 95% and one-fifth showed high adherence at 6 months.

With millions of Americans affected by sexually transmitted infections (STI) an emphasis on prevention and control strategies was included in the recommendations.

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.

Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.

In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.

US residents with HIV have higher rates of mortality than their peers without infection, but the gap is narrowing, a recent study showed.

Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.

The pandemic's effect on in-person care prioritization may have indirectly influenced the rate of screening opportunities in at-risk persons.

New findings from CUSTOMIZE suggest the once-monthly injection therapy was feasibly implemented and generally favored to once-daily tablets.